Kestra Medical officer proposes $314K share sale
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Kestra Medical Technologies, Ltd. (KMTS) officer and director Brian Daniel Webster reported a proposed sale of 15,000 common shares, with an aggregate market value of $314,329.85 and an approximate sale date of May 15, 2026. He acquired the shares on January 21, 2026, in a restricted share issuance granted under the issuer's equity compensation plan. During the preceding three months, he reported sales of 15,000 shares on February 17 for gross proceeds of $384,020.06, 15,000 on March 17 for $304,123.49, and 15,000 on April 15 for $300,671.04. The date reported for plan adoption or giving of instruction, if relying on Rule 10b5-1, is September 29, 2025.
Key Figures
Key Terms
equity compensation plan financial
Rule 10b5-1 regulatory
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.